Skip to content
‹ Back to IndustriesHealthcare

High Costs, Low Margins, and Regulatory Hurdles Hinder Pharma’s Adoption of Advanced Manufacturing Technologies

Pharmaceutical manufacturers face financial and regulatory barriers that outweigh the benefits of modernizing their production processes

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

By Mike Tracy · · Advanced Manufacturing TechnologiesDrug ProductionDrug ShortageMike Tracy
Share

Key takeaways

01

Pharmaceutical manufacturers face financial and regulatory barriers that outweigh the benefits of modernizing their production processes

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The ongoing drug shortage crisis in the U.S. underscores a critical need for innovation in pharmaceutical manufacturing. As manufacturing issues, outdated technologies, and geopolitical risks contribute to shortages that impact patient care and elevate healthcare costs, the introduction of Advanced Manufacturing Technologies (AMTs) offers a beacon of hope. AMT technologies promise to enhance quality control and reduce production downtime, yet their adoption in generic drug production remains low despite obvious benefits.

Why is the pharmaceutical industry slow to adopt technologies that could revolutionize drug availability and cost?

Mike Tracy, a C-Level Healthcare Operations Strategist, dives into the complexities of integrating Advanced Manufacturing Technologies in drug production. Mike points out that while AMTs can drastically reduce bottlenecks in drug production, the significant initial investment and stringent regulatory landscape pose substantial hurdles.

“Every AMT has a high startup cost and generic drugs have very razor-thin margins to begin with. We’re not talking about a new drug that’s not already out in the market where you’re going to have a high margin and it makes sense to invest millions,” Tracy explains.

Every AMT has a high startup cost and generic drugs have very razor-thin margins to begin with.
— Mike Tracy, C-Level Healthcare Operations Strategist

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

Mike Tracy
Mike TracyChief Operating Officer at enGen

With a fulfilling history within the healthcare industry, Mike establish thoughtful, metric-based direction for new and improved initiatives, processes, and programs to refresh employee engagement, satisfy customers, and revamp operational efficiencies. By employing effective cost analysis, he identify avenues for appropriate cost reductions without jeopardizing staffing and operation needs. For example, Mike accomplished a 20% reduction in SG&A cost for technology by engineering a standard operating model, automation development, and revising processes in my current position. Alongside expert cost analysis, he ensure all implementations align with company goals and missions while assessing community needs.

B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Why hospitals stagger security upgrades instead of shutting down

Why hospitals stagger security upgrades instead of shutting down

Parabit Systems' Robert Iraggi told A Weekly Bit that hospital security upgrades must be planned and staggered because the building never closes. OSHA counted 7.8 serious violent injuries per 10,000 healthcare workers in 2013 against under two in construction, and Joint Commission EP 17 requires an annual worksite analysis. Illinois biometric law adds a consent step for facial recognition.

  • 01OSHA counted 7.8 serious violent injuries per 10,000 healthcare workers in 2013; construction, manufacturing and retail each stayed under two.
  • 02Joint Commission EP 17 has required an annual workplace violence worksite analysis since January 2022, and hospitals are expected to act on what it finds—making phased security upgrades easier to document year to year.
  • 03Squire Patton Boggs counted at least 100 Illinois biometric privacy class actions filed in 2025, and Illinois’ BIPA requires notice and consent for collecting biometrics—so a facial-recognition rollout plan should include the notice, consent record, and retention controls before the first camera goes live.

Nov 17, 2026

Sterile processing deviations become the norm without stop-and-document rules

Sterile processing deviations become the norm without stop-and-document rules

Advanced Sterilization Products' Tamara Beeler told Censis Technologies' CtUC 2026 audience that sterile processing deviations harden into norms when departments don’t stop, escalate and document them. She connects ANSI/AAMI ST108:2023 water categories, daily cleaning verification, loaner-tray refusal when sets arrive late or lack IFUs, and root cause analysis when rework repeats on the same device.

  • 01ANSI/AAMI ST108:2023 turned water quality for instrument reprocessing into an enforceable standard; AAMI's earlier TIR34 was guidance with no enforcement behind it.
  • 02Some facilities require loaner trays 48 hours before a case, and ASP's Tamara Beeler says a technician at any level can refuse one that arrives late, undocumented or dirty.
  • 03Rework that returns on the same device is the point at which Beeler wants a root cause analysis opened, with the record kept in the instrument tracking system.

Nov 17, 2026

TheraPanacea aims to spread best-center radiotherapy quality

TheraPanacea aims to spread best-center radiotherapy quality

TheraPanacea CEO Nikos Paragios says the company's two objectives are to carry best-center radiotherapy quality to every patient and to pick each patient's treatment at the start from multimodal data. A 2026 Nature Communications trial of 500 patients found AI-assisted contouring lifted mean Dice overlap from 0.857 to 0.902, and Siemens Healthineers CE-marked its own AI contouring in May 2026.

  • 01TheraPanacea's two stated objectives: carry best-center radiotherapy quality to every patient on the globe, and identify each patient's best treatment at the start from imaging and clinical history.
  • 02A 2026 Nature Communications trial of 500 patients across five centers found AI-assisted contouring lifted mean Dice overlap from 0.857 to 0.902 and cut median contouring time from 55 to 10 minutes, with less variation between centers.
  • 03Siemens Healthineers' Varian business CE-marked AI contouring for Eclipse in May 2026, so Paragios locates TheraPanacea's edge in its team, hospital partnerships and impact focus rather than in the algorithm alone.

Nov 17, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

Mike Tracy
Mike Tracy

Chief Operating Officer at enGen

With a fulfilling history within the healthcare industry, Mike establish thoughtful, metric-based direction for new and improved initiatives, processes, and programs to refresh employee engagement, satisfy customers, and revamp operational efficiencies. By employing effective cost analysis, he identify avenues for appropriate cost reductions without jeopardizing staffing and operation needs. For example, Mike accomplished a 20% reduction in SG&A cost for technology by engineering a standard operating model, automation development, and revising processes in my current position. Alongside expert cost analysis, he ensure all implementations align with company goals and missions while assessing community needs.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512